CN115867539A - 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用 - Google Patents

2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用 Download PDF

Info

Publication number
CN115867539A
CN115867539A CN202180048966.0A CN202180048966A CN115867539A CN 115867539 A CN115867539 A CN 115867539A CN 202180048966 A CN202180048966 A CN 202180048966A CN 115867539 A CN115867539 A CN 115867539A
Authority
CN
China
Prior art keywords
deuterium
radical
substituted
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180048966.0A
Other languages
English (en)
Inventor
赵保卫
张鸣鸣
喻红平
陈椎
徐耀昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbisko Therapeutics Co Ltd
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of CN115867539A publication Critical patent/CN115867539A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems

Abstract

涉及了2,3‑二氢‑1H‑吡咯并[3,2‑b]吡啶衍生物、其制备方法和应用。特别地涉及一种具有式(I)结构的EGFR抑制剂及其制备方法、含有其的药物组合物,以及其作为EGFR抑制剂的用途和其在治疗和/或预防至少部分由与EGFR外显子20插入或缺失突变相关的癌症、肿瘤或转移性疾病中的用途,特别是在治疗过度增殖性疾病和诱导细胞死亡障碍疾病中的用途。其中式(I)的各取代基与说明书中的定义相同。

Description

PCT国内申请,说明书已公开。

Claims (22)

  1. PCT国内申请,权利要求书已公开。
CN202180048966.0A 2020-12-02 2021-12-01 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用 Pending CN115867539A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020114004319 2020-12-02
CN202011400431 2020-12-02
PCT/CN2021/134790 WO2022116995A1 (zh) 2020-12-02 2021-12-01 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用

Publications (1)

Publication Number Publication Date
CN115867539A true CN115867539A (zh) 2023-03-28

Family

ID=81852959

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180048966.0A Pending CN115867539A (zh) 2020-12-02 2021-12-01 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用

Country Status (7)

Country Link
US (1) US20240109885A1 (zh)
EP (1) EP4257584A1 (zh)
JP (1) JP2023545571A (zh)
CN (1) CN115867539A (zh)
CA (1) CA3196068A1 (zh)
TW (1) TW202227439A (zh)
WO (1) WO2022116995A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106928150A (zh) * 2015-12-31 2017-07-07 恩瑞生物医药科技(上海)有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN108864079A (zh) * 2017-05-15 2018-11-23 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
CN109328059A (zh) * 2016-01-07 2019-02-12 Cs制药技术有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
WO2022033455A1 (zh) * 2020-08-13 2022-02-17 上海和誉生物医药科技有限公司 具有egfr抑制活性的三嗪衍生物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016029839A1 (zh) * 2014-08-25 2016-03-03 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106928150A (zh) * 2015-12-31 2017-07-07 恩瑞生物医药科技(上海)有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN109328059A (zh) * 2016-01-07 2019-02-12 Cs制药技术有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN108864079A (zh) * 2017-05-15 2018-11-23 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
WO2022033455A1 (zh) * 2020-08-13 2022-02-17 上海和誉生物医药科技有限公司 具有egfr抑制活性的三嗪衍生物及其制备方法和应用

Also Published As

Publication number Publication date
EP4257584A1 (en) 2023-10-11
WO2022116995A1 (zh) 2022-06-09
US20240109885A1 (en) 2024-04-04
CA3196068A1 (en) 2022-06-09
JP2023545571A (ja) 2023-10-30
TW202227439A (zh) 2022-07-16

Similar Documents

Publication Publication Date Title
TWI751155B (zh) 經胺取代之芳基或雜芳基化合物
TWI714567B (zh) 作為lsd1抑制劑之雜環化合物
CN112368283B (zh) 含二并环类衍生物抑制剂、其制备方法和应用
CN113396147A (zh) 芳香杂环类衍生物调节剂、其制备方法和应用
CN113801114B (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
WO2016054987A1 (zh) Egfr抑制剂及其制备和应用
TW202102505A (zh) 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用
CN115605479A (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
CN112292378A (zh) 含吲哚类衍生物抑制剂、其制备方法和应用
WO2022247816A1 (zh) 含氮杂环类化合物、其制备方法及其在医药上的应用
CN113366008A (zh) 一种cd73抑制剂,其制备方法和应用
CN115836064A (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
CN115867539A (zh) 2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
CN115836070A (zh) 作为egfr抑制剂的稠环化合物及其制备方法和应用
CN112812105A (zh) 一种氨基吡啶基氧基吡唑类衍生物及其制备方法和应用
WO2020233645A1 (zh) 大环类衍生物、及其制备方法和用途
WO2023011505A1 (zh) 嘧啶或吡啶衍生物及其制备方法和在药学上的应用
CN113861195B (zh) 一种多稠环egfr抑制剂及其制备方法和应用
CN113912608B (zh) 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用
CN115701429A (zh) 4-(1h-吲哚-1-基)嘧啶-2-氨基衍生物及其制备方法和应用
WO2024022286A1 (zh) 大环egfr抑制剂及其制备方法和药学上的应用
TW202241862A (zh) 二甲醯胺類化合物、其製備方法及其在醫藥上的應用
WO2022122037A1 (zh) 一种二氢异喹啉酮衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082453

Country of ref document: HK